Browsing by Author "Xu, Xuejun"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Novel anti-inflammatory peptide alleviates liver ischemia-reperfusion injury
    (Journal of Biomedical Research, 2024-04-30) Xu, Xuejun; Sun, Kaineng; Chang, Hao; Shen, Chunxiang; Li, Xiangdong; Ni, Yangyue; Zhu, Yuxiao; Wang, Huiquan; Xiong, Ruiyan; Padde, Jon Rob; Xu, Zhipeng; Chen, Lin; Chen, Lu; Hou, Min; Pu, Liyong; Ji, Minjun
    Ischemia-reperfusion injury (IRI) remains inevitable in liver surgeries, macrophages play a critical role in the development of IRI, but little is known about the macrophages regulate pathogenesis of IRI. Based on target guided screening, we identified a small 3 kDa peptide (SjDX5-271) from various schistosome egg-derived peptides that induced M2 macrophage polarization. SjDX5-271 treatment protected the mice against liver IRI through promoting M2 macrophage polarization, the protective effect was abrogated when the macrophages were depleted. Transcriptomic sequencing showed that the TLR signaling pathway was significantly inhibited in macrophages derived from the SjDX5-271 treatment group. We further identified that SjDX5-271 promotes M2 macrophage polarization by inhibiting the TLR4/MyD88/NF-κB signaling pathway and further alleviates hepatic inflammation in liver IRI. Collectively, SjDX5-271 exhibits promising therapeutic effects in IRI and represents a novel therapeutic approach for IRI, even in immune-related diseases. This study revealed the development of a new biologic from the parasite and enhanced our understanding of host-parasite interplay, providing a blueprint for future therapies for immune-related diseases.
  • Thumbnail Image
    Item
    A target-based discovery from a parasitic helminth as a novel therapeutic approach for autoimmune diseases.
    (eBioMedicine, 2023-08-12) Ni, Yangyue; Xiong, Ruiyan; Zhu, Yuxiao; Luan, Ning; Yu, Chuanxin; Yang, Kun; Wang, Huiquan; Xu, Xuejun; Yang, Yuxuan; Sun, Siyu; Shi, Liyun; Chen, Lin; Chen, Lu; Hou, Min; Xu, Zhipeng; Lai, Ren; Jia, Minjun
    Background: Regulatory T cells (Tregs) can alleviate the development of autoimmune and inflammatory diseases, thereby proposing their role as a new therapeutic strategy. Parasitic helminths have co-evolved with hosts to generate immunological privilege and immune tolerance through inducing Tregs. Thus, constructing a “Tregs-induction”-based discovery pipeline from parasitic helminth is a promising strategy to control autoimmune and inflammatory diseases. Methods: The gel filtration chromatography and reverse-phase high-performance liquid chromatography (RP-HPLC) were used to isolate immunomodulatory components from the egg extracts of Schistosoma japonicum. The extracted peptides were evaluated for their effects on Tregs suppressive functions using flow cytometry, ELISA and T cell suppression assay. Finally, we carried out colitis and psoriasis models to evaluate the function of Tregs induced by helminth-derived peptide in vivo. Findings: Here, based on target-driven discovery strategy, we successfully identified a small 3 kDa peptide (SjDX5-53) from egg extracts of schistosome, which promoted both human and murine Tregs production. SjDX5-53 presented immunosuppressive function by arresting dendritic cells (DCs) at an immature state and augmenting the proportion and suppressive capacity of Tregs. In mouse models, SjDX5-53 protected mice against autoimmune-related colitis and psoriasis through inducing Tregs and inhibiting inflammatory T-helper (Th) 1 and Th17 responses. Interpretation: SjDX5-53 exhibited the promising therapeutic effects in alleviating the phenotype of immune-related colitis and psoriasis. This study displayed a screening and validation pipeline of the inducer of Tregs from helminth eggs, highlighting the discovery of new biologics inspired by co-evolution of hosts and their parasites. Funding: This study was supported by the Natural Science Foundation of China (82272368) and Natural Science Foundation of Jiangsu Province (BK20211586).